Clinical features of patients with pancreatic neuroendocrine tumor and influencing factors for prognosis

Chen FeiFan; Chen CongYing; Zhang YaJing; Zhang YiYi; Huang YinShi; Xu Min

doi:10.3969/j.issn.1001-5256.2020.02.034

Volume 36 Issue 2

Feb. 2020

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2020 > 36(2): 399-403

PDF( 1972 KB)

Clinical features of patients with pancreatic neuroendocrine tumor and influencing factors for prognosis

DOI: 10.3969/j.issn.1001-5256.2020.02.034

Shanghai Key Laboratory for Pancreatic Diseases,Department of Gastroenterology,The First Affiliated People's Hospital of Shanghai Jiao Tong University

Research funding:

Received Date: 2019-11-16
Published Date: 2020-02-20

Abstract

Abstract

Objective To investigate the clinical features of patients with pancreatic neuroendocrine tumor( PNET) and the influencing factors for prognosis. Methods A retrospective analysis was performed for the clinical data of 54 patients with pathologically confirmed PNET in The First Affiliated People's Hospital of Shanghai Jiao Tong University from March 2012 to April 2019,and clinical,pathological,and imaging features and prognosis were analyzed. The chi-square test or the Fisher's exact test was used for comparison of categorical data between groups. The Kaplan-Meier method was used for survival analysis,and the log-rank test was used for comparison between groups.Results Among the 54 patients,there were 19 male patients( 35. 2%) and 35 female patients( 64. 8%). Of all patients,47( 87. 0%)had non-functional tumors and 7( 13. 0%) had functional tumors. There were 17 patients( 31. 5%) with TNM stage Ⅰ tumor,26 patients( 48. 1%) with stage Ⅱ tumor,9 patients( 16. 7%) with stage Ⅲ tumor,and 2 patients( 3. 7%) with stage Ⅳ tumor. According to the World Health Organization pathological grade,24 patients( 46. 2%) had G1 tumor,22( 42. 3%) had G2 tumor,and 6( 11. 5%) had G3 tumor. The patients with unclear boundary of tumor on CT( χ2= 8. 250,P = 0. 010) and MRI( χ2= 6. 048,P = 0. 031) tended to have higher postoperative recurrence rate and mortality rate. Overall survival time ranged from 1 to 86 months,with a 5-year survival rate of92. 0% and a disease-free survival time of 1-71 months. The univariate analysis showed that TNM stage( χ2= 9. 572,P = 0. 023),pathological grade( χ2= 7. 506,P = 0. 023),surgical margin invasion( χ2= 15. 123,P < 0. 001),lymph node metastasis( χ2= 4. 716,P =0. 030),and distant metastasis( χ2= 5. 534,P = 0. 019) were associated with overall survival time in the patients with PNET. Conclusion PNET patients with unclear tumor boundary on CT and MRI tend to have poor prognosis. TNM stage,pathological grade,surgical margin invasion,lymph node metastasis,and distant metastasis are closely associated with the prognosis of patients with PNET.
- pancreatic neoplasms,
- neuroendocrine tumors,
- disease attributes,
- prognosis

FullText(HTML)

References(23)

References

[1] REID MD,BALCI S,SAKA B,et al. Neuroendocrine tumors of the pancreas:Current concepts and controversies[J]. Endocr Pathol,2014,25(1):65-79.

[2] SUN HT,ZHANG SL,LIU K,et al. MRI-based nomogram estimates the risk of recurrence of primary nonmetastatic pancreatic neuroendocrine tumors after curative resection[J]. J Magn Reson Imaging,2019,50(2):397-409.

[3] BASHIR MR,GUPTA RT. MDCT evaluation of the pancreas:Nuts and bolts[J]. Radiol Clin North Am,2012,50(3):365-377.

[4] BOSMAN FT,CARNEIRO F,HRUBAN RH,et al. WHO classification of tumors of the digestive system[M]. 4th edition. Lyon:International Agency for Research on Cancer,2010.

[5] BRIERLEY JD,GOSPODAROWICZ K,WITTEKIND C,et al.TNM classification of malignant tumors[M]. 8th edition. UK:Wiley Blackwell,2017.

[6] ZHANG TP,QIU JD,FENG MY,et al. Progress and controversy on the treatment of incidental non-functioning pancreatic neuroendocrine tumors[J]. Chin J Dig Surg,2018,17(7):666-670.(in Chinese)张太平，邱江东，冯梦宇，等．偶发无功能胰腺神经内分泌肿瘤的治疗进展与争议[J]．中华消化外科杂志，2018,17(7):666-670.

[7] DE ROBERTIS R,CINGARLINI S,TINAZZI MARTINI P,et al.Pancreatic neuroendocrine neoplasms:Magnetic resonance imaging features according to grade and stage[J]. World J Gastroenterol,2017,23(2):275-285.

[8] GUO CG,REN S,CHEN X,et al. Pancreatic neuroendocrine tumor:Prediction of the tumor grade using magnetic resonance imaging findings and texture analysis with 3-T magnetic resonance[J]. Cancer Manag Res,2019,11:1933-1944.

[9] KIM DW,KIM HJ,KIM KW,et al. Neuroendocrine neoplasms of the pancreas at dynamic enhanced CT:Comparison between grade 3 neuroendocrine carcinoma and grade 1/2 neuroendocrine tumour[J]. Eur Radiol,2015,25(5):1375-1383.

[10] KIM JH,EUN HW,KIM YJ,et al. Pancreatic neuroendocrine tumour(PNET):Staging accuracy of MDCT and its diagnostic performance for the differentiation of PNET with uncommon CT findings from pancreatic adenocarcinoma[J]. Eur Radiol,2016,26(5):1338-1347.

[11] CANELLAS R,LO G,BHOWMIK S,et al. Pancreatic neuroendocrine tumor:Correlations between MRI features,tumor biology,and clinical outcome after surgery[J]. J Magn Reson Imaging,2018,47(2):425-432.

[12] ZHAO XD,TIAN XD,YANG YM. Diagnosis and surgical treatment of pancreatic neuroendocrine neoplasms[J]. Chin J Hepatobiliary Surg,2017,23(8):505-508.(in Chinese)赵旭东，田孝东，杨尹默．胰腺神经内分泌肿瘤的诊断与外科治疗[J]．中华肝胆外科杂志，2017,23(8):505-508.

[13] YANG M,ZHANG Y,ZENG L,et al. Prognostic validity of the American Joint Committee on Cancer eighth edition TNM staging system for surgically treated and well-differentiated pancreatic neuroendocrine tumors:A comprehensive analysis of254 consecutive patients from a large Chinese institution[J].Pancreas,2019,48(5):613-621.

[14] PAVEL M,O’TOOLE D,COSTA F,et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal,pancreatic,bronchial neuroendocrine neoplasms(NEN)and NEN of unknown primary site[J]. Neuroendocrinology,2016,103(2):172-185.

[15] YAO JC,PAVEL M,LOMBARD-BOHAS C,et al. Everolimus for the treatment of advanced pancreatic neuroendocrine tumors:Overall survival and circulating biomarkers from the randomized,phase III RADIANT-3 study[J]. J Clin Oncol,2016,34(32):3906-3913.

[16] FAIVRE S,NICCOLI P,CASTELLANO D,et al. Sunitinib in pancreatic neuroendocrine tumors:Updated progressionfree survival and final overall survival from a phase III randomized study[J]. Ann Oncol,2017,28(2):339-343.

[17] IMHOF A,BRUNNER P,MARINCEK N,et al. Response,survival,and long-term toxicity after therapy with the radiolabeled somatostatin analogue[90Y-DOTA]-TOC in metastasized neuroendocrine cancers[J]. J Clin Oncol,2011,29(17):2416-2423.

[18] LUO Q,LIU YN,MA HY,et al. Analysis of diagnosis,therapy and prognosis factors of 103 patients with pancreatic neuroendocrine tumors[J]. Chin J Surg,2017,55(10):755-759.(in Chinese)罗乔，刘艳楠，马洪运，等．胰腺神经内分泌肿瘤103例诊治经验及预后因素分析[J]．中华外科杂志，2017,55(10):755-759.

[19] SHEN C,DASARI A,CHU Y,et al. Clinical,pathological,and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors[J]. Ann Oncol,2017,28(7):1582-1589.

[20] YANG M,TIAN B,ZHANG Y,et al. Epidemiology,diagnosis,surgical treatment and prognosis of the pancreatic neuroendocrine tumors:Report of 125 patients from one single center[J]. Indian J Cancer,2015,52(3):343-349.

[21] ZHANG P,LI YL,QIU XD,et al. Clinicopathological characteristics and risk factors for recurrence of wel-differentiated pancreatic neuroendocrine tumors after radical surgery:A case-control study[J]. World J Surg Oncol,2019,17(1):66.

[22] BALLIAN N,LOEFFLER AG,RAJAMANICKAM V,et al. A simplified prognostic system for resected pancreatic neuroendocrine neoplasms[J]. HPB(Oxford),2009,11(5):422-428.

[23] FISHER AV,LOPEZ-AGUIAR AG,RENDELL VR,et al. Predictive value of chromogranin A and a pre-operative risk score to predict recurrence after resection of pancreatic neuroendocrine tumors[J]. J Gastrointest Surg,2019,23(4):651-658.

Relative Articles

[1]	Xiaoxuan XIE, Lina DU, Ziyun GUO, Yan YANG. Role of apical sodium-dependent bile acid transporter in hepatobiliary diseases[J]. Journal of Clinical Hepatology, 2024, 40(1): 199-203. doi: 10.12449/JCH240133
[2]	Long HUANG, Yu CHEN, Qiao WU, Zhongping DUAN. Effect of Shuganning injection on the model of cholestasis - type chlorpromazine - induced liver injury constructed by a new tissue - engineered liver[J]. Journal of Clinical Hepatology, 2022, 38(3): 587-593. doi: 10.3969/j.issn.1001-5256.2022.03.018
[3]	Huaqian XU, Meng WEI, Xue ZHANG, Hai YI, Fangyi FAN, Aiping HUANG, Shanhong TANG. Diffuse large B-cell lymphoma with severe cholestasis as the main manifestation: A case report[J]. Journal of Clinical Hepatology, 2022, 38(12): 2821-2823. doi: 10.3969/j.issn.1001-5256.2022.12.025
[4]	Bo YI, Xue LI, Shanhong TANG. Research advances in the mechanism of abnormal bile acid metabolism caused by gene mutation[J]. Journal of Clinical Hepatology, 2022, 38(9): 2136-2140. doi: 10.3969/j.issn.1001-5256.2022.09.036
[5]	Xiaoqiang GAO, Shi ZUO, Xiaodong JIA, Yinying LU. Research advances in sodium taurocholate cotransporting polypeptide in hepatobiliary diseases[J]. Journal of Clinical Hepatology, 2022, 38(5): 1179-1182. doi: 10.3969/j.issn.1001-5256.2022.05.043
[6]	Jing LI, Kuiyang ZHENG, Beibei ZHANG. Mechanism of action of bile acid metabolism in regulating cholestatic liver disease and the research and development of drugs[J]. Journal of Clinical Hepatology, 2021, 37(10): 2482-2487. doi: 10.3969/j.issn.1001-5256.2021.10.048
[7]	WU Rong, LING AiMin. Primary biliary cirrhosis with autoimmune hemolytic anemia: A case report[J]. Journal of Clinical Hepatology, 2020, 36(12): 2795-2797. doi: 10.3969/j.issn.1001-5256.2020.12.030
[8]	Hua HaiYang, Li JianHui, Su Bin, Xuan XiaoYu. Liver subcapsular biliary cyst successfully treated by endoscopic retrograde cholangiopancreatography: A case report[J]. Journal of Clinical Hepatology, 2020, 36(6): 1354-1355. doi: 10.3969/j.issn.1001-5256.2020.06.034
[9]	Shen Hong, Hu Meng, Wei ZeHui, Zhang Dong, Zhang JunChang, Tian GuangJun. Bile formation, secretion, and excretion and the pathogenesis of cholestasis[J]. Journal of Clinical Hepatology, 2019, 35(2): 431-437. doi: 10.3969/j.issn.1001-5256.2019.02.043
[10]	Zhou Fang, Li XiaoQin, Wang RuiFeng, Sun Bo. X-linked lymphoproliferative disease type 2 with cholestatic liver disease as initial manifestation: A case report[J]. Journal of Clinical Hepatology, 2019, 35(8): 1811-1814. doi: 10.3969/j.issn.1001-5256.2019.08.034
[11]	Kan YanTing, Yang YongFeng. Role of cholestatic liver disease-related genes in intrahepatic cholestasis of pregnancy[J]. Journal of Clinical Hepatology, 2019, 35(7): 1439-1443. doi: 10.3969/j.issn.1001-5256.2019.07.006
[12]	Song YuanZong. Research advances in the pathogenesis, clinical manifestations, and diagnosis/treatment of sodium-taurocholate cotransporting polypeptide deficiency[J]. Journal of Clinical Hepatology, 2019, 35(8): 1690-1692. doi: 10.3969/j.issn.1001-5256.2019.08.007
[13]	Xu Feng, Liu XiaoLin, Wang Chao, Dai ChaoLiu. Protective effect of prostaglandin E1 pretreatment against liver ischemia-reperfusion injury in rats with cholestasis[J]. Journal of Clinical Hepatology, 2017, 33(5): 899-904. doi: 10.3969/j.issn.1001-5256.2017.05.022
[14]	Zhang XuQian, Zhao ChunShan, Liu WenTian, Wang BangMao, Zhou Lu. Elevated serum GGT level in recovery phase of cholestatic liver disease reveals good prognosis: a case report [J]. Journal of Clinical Hepatology, 2016, 32(4): 774-775. doi: 10.3969/j.issn.1001-5256.2016.04.037
[15]	Shen FeiFei, Lu LunGen. Liver alkaline phosphatase: a marker of cholestasis and bile duct injury[J]. Journal of Clinical Hepatology, 2016, 32(5): 1026-1030. doi: 10.3969/j.issn.1001-5256.2016.05.052
[16]	Li Hua, Li YiMing, Lu Le. Mechanism of α-naphthyl isothiocyanate inducing cholestatic hepatitis: a preliminary study[J]. Journal of Clinical Hepatology, 2016, 32(5): 933-937. doi: 10.3969/j.issn.1001-5256.2016.05.026
[17]	Li Lei, Li Bing, Ding HuiGuo. Effect of ursodeoxycholic acid on bile secretion after endoscopic nasobiliary drainage in patients with cholestatic liver disease of various causes[J]. Journal of Clinical Hepatology, 2016, 32(3): 522-525. doi: 10.3969/j.issn.1001-5256.2016.03.026
[18]	Guo HongMei, Zheng BiXia, Li Mei. Neonatal intrahepatic cholestasis caused by citrin deficiency due to SLC25A13 gene mutations: a clinical analysis of 21cases in Nanjing, China[J]. Journal of Clinical Hepatology, 2014, 30(11): 1127-1131. doi: 10.3969/j.issn.1001-5256.2014.11.008
[19]	Lu LunGen. Mechanism of bile secretion, excretion, regulation and cholestasis[J]. Journal of Clinical Hepatology, 2011, 27(6): 570-571+580.
[20]	Qu Ying, Xu MingYi, Lu LunGen. Current progress in understanding of cholestasis and autoimmune liver diseases——Meeting review about 1st symposium on cholestasis and autoimmune liver disease[J]. Journal of Clinical Hepatology, 2011, 27(2): 222-225.

Supplements(0)

Cited By

Cited by

Periodical cited type(8)

1.	张连峰，杨丽敏. 胸腺肽肠溶片联合聚乙二醇干扰素对慢性肝炎患者的治疗效果及其相关指标的影响. 中国当代医药. 2020(04): 50-52 .
2.	王雪云，孙敏，赵巧云，李红军，王先芝，郑玉山，边城. 聚乙二醇干扰素联合富马酸替诺福韦治疗慢性乙型肝炎的疗效观察. 医学信息. 2020(04): 144-146 .
3.	刘征. 恩替卡韦联合α-干扰素对慢性乙型肝炎患者血清ALT复常率的影响. 淮海医药. 2020(02): 181-183 .
4.	李淑，彭雁忠，胡国信，齐明华，武敬. 聚乙二醇干扰素治疗低水平HBsAg慢性乙肝患者疗效. 中国热带医学. 2020(07): 676-681 .
5.	嵇玮嘉，颜学兵. 聚乙二醇干扰素α-2a与聚乙二醇干扰素α-2b治疗慢性乙型肝炎的效果及安全性比较. 临床肝胆病杂志. 2019(02): 309-314 . 本站查看
6.	吴明杰. 聚乙二醇干扰素α-2b对慢性乙型肝炎的作用分析. 中国继续医学教育. 2019(12): 142-144 .
7.	张珊，王艺璇，孙静，朱琳，王凤水，邢卉春. 干扰素联合抗病毒治疗对提高核苷（酸）类药物经治慢性乙型肝炎患者表面抗原阴转率的影响. 中华实验和临床感染病杂志(电子版). 2019(04): 273-280 .
8.	郭志勇，贺文娟，裴军芳. 聚乙二醇干扰素α-2a注射液联合替诺福韦酯治疗e抗原阳性慢性乙型肝炎疗效分析. 中国药物与临床. 2019(22): 3944-3946 .

Other cited types(4)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1297) PDF downloads(190)

Clinical features of patients with pancreatic neuroendocrine tumor and influencing factors for prognosis

DOI: 10.3969/j.issn.1001-5256.2020.02.034